Antacids Market - By Drug Class (Proton Pump Inhibitors, Acid Neutralizers, Anti-H. Pyloric Drugs), Indication (Gastroesophageal Reflux Disease, Heartburn, Gastritis), Dosage, Route of Administration, Distribution Channel - Global Forecast (2024

Description

Global Antacids Market size will expand at a 5.1% CAGR between 2024 and 2032, attributed to advances in formulation and delivery methods. Innovations such as chewable tablets, fast-dissolving powders, and convenient liquid forms enhance the effectiveness and user experience of antacids. Furthermore, greater awareness about digestive health and the heightened rate of digestive disorders encourages consumers to seek effective over-the-counter solutions. This combination of technological improvements and increased health consciousness contributes to a rising demand for diverse and advanced antacid products, fueling market expansion.

For instance, in June 2024, Akums Drugs & Pharmaceuticals Ltd. launched a new anti-reflux chewable tablet containing sodium alginate and potassium bicarbonate, which has been approved by the Drugs Controller General of India (DCGI). This innovation reflects growing advancements in antacid formulations, catering to the increasing demand for effective, user-friendly digestive solutions. The approval highlights the rising regulatory support for new antacid products, while the introduction of such advanced formulations can drive market growth by offering enhanced relief options and expanding consumer choice globally.

The antacids industry is fragmented based on drug class, indication, dosage, route of administration, distribution channel, and region.

The acid neutralizers segment will observe a noteworthy surge through 2032, spurred by their immediate effectiveness in relieving heartburn and acid indigestion. These products, which include calcium carbonate and magnesium hydroxide, work by directly neutralizing stomach acid, providing rapid symptom relief. Their widespread availability over the counter and acceptance by consumers as a quick solution for digestive discomfort contribute to their dominant market position. The growing prevalence of gastroesophageal reflux disease (GERD) further boosts the demand for acid neutralizers.

The heartburn segment will undergo a remarkable upturn by 2032, owing to the widespread occurrence of this condition among adults. Heartburn, often caused by gastroesophageal reflux disease (GERD), drives a significant demand for over-the-counter antacids that provide quick and effective relief. The availability of various formulations, such as tablets, liquids, and chewables, caters to diverse consumer preferences, further boosting market growth. Also, increasing awareness about managing heartburn symptoms and the convenience of self-medication contribute to the segment's dominance.

Asia Pacific antacids market share will experience a notable CAGR from 2024 to 2032 due to the region's high prevalence of digestive disorders and growing healthcare awareness. Rapid urbanization, changing dietary habits, and increased stress levels contribute to the rising incidence of heartburn and acid reflux in countries like China and India. Besides, the expanding middle-class population and improved access to healthcare products are driving the demand for antacids. The region's growing focus on managing digestive health effectively positions Asia Pacific as a crucial contributor to the antacids industry.

Product Code: 9703

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of gastrointestinal disorders
  - 3.2.1.2 Dietary and lifestyle changes
  - 3.2.1.3 Increased awareness and self-medication
  - 3.2.1.4 Pharmaceutical advancements
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Side effects and health risks
  - 3.2.2.2 Availability of substitutes
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Pricing analysis, 2023
- 3.6.1 By region
- 3.6.2 By key player
3.7 Future market trends
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Proton pump inhibitors
5.3 Acid neutralizers
5.4 Anti-H.pyloric drugs
5.5 H2 antagonists
5.6 Pro-motility agents
5.7 Prostaglandin analogous
5.8 Other drug classes

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Gastroesophageal reflux disease
6.3 Heartburn
6.4 Indigestion
6.5 Gastritis
6.6 Peptic ulcer disease
6.7 Other indications

Chapter 7 Market Estimates and Forecast, By Dosage, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Tablets
7.3 Liquid
7.4 Other dosages

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Oral
8.3 Injectable

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Hospital pharmacy
9.3 Online pharmacy
9.4 Retail pharmacy

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
- 10.5.4 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 Saudi Arabia
- 10.6.2 South Africa
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

11.1 Aurobindo Pharma Limited
11.2 Bayer AG
11.3 Bristol Myers Squibb Company
11.4 Cipla Limited
11.5 Dr. Reddy's Laboratories Ltd.
11.6 F. Hoffmann-La Roche Ltd.
11.7 Gsk plc
11.8 Hikma Pharmaceuticals PLC
11.9 Lupin Limited
11.10 Novartis AG
11.11 Pfizer Inc.
11.12 Sun Pharmaceutical Industries Ltd
11.13 Teva Pharmaceutical Industries Ltd
11.14 The Procter & Gamble Company
11.15 Viatris Inc.

Antacids Market - By Drug Class (Proton Pump Inhibitors, Acid Neutralizers, Anti-H. Pyloric Drugs), Indication (Gastroesophageal Reflux Disease, Heartburn, Gastritis), Dosage, Route of Administration, Distribution Channel - Global Forecast (2024 - 2032)